Cellectar Biosciences Announces Positive DMC Review of Pivotal Trial of Iopofosine in Waldenstrom’s Macroglobulinemia Apr 26, 2022
Cellectar Reports Financial Results for Year Ended December 2021 and Provides a Corporate Update Mar 21, 2022
Cellectar Presented Data from its Ongoing Phase 2 CLOVER-1 Study of Iopofosine I-131 at the 63rd ASH Annual Meeting and Exposition Dec 13, 2021
Cellectar Biosciences Announces Poster Presentation at the 63rd American Society for Hematology Annual Meeting and Exposition Dec 8, 2021
Cellectar’s Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors Nov 16, 2021
Cellectar Reports Financial Results for the Third Quarter 2021 and Provides a Corporate Update Nov 8, 2021
